Results from the phase 1b MajesTEC-2 trial showed that teclistamab plus daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.
Russ Conroy
Advertisement
Articles by Russ Conroy
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
June 2026 in Oncology: A Look Back at FDA Approvals and Decisions
2
New Considerations Arise in Sequencing After Second Relapse in Multiple Myeloma
3
SC Amivantamab Plus Lazertinib Builds on Evolving Frontline Paradigm in EGFR+ NSCLC
4
Orca-T Gains FDA Approval in Matched Donor Transplants
5